What is the Gemfibrozil?

Gemfibrozil is White crystalline powder, while it's Molecular Formula is C15H22O3. White crystalline powder Gemfibrozil has been used to to study its effects on cell cycle progression in yeast. It has been used to study the effects of fibrates on cell proliferation and gene expression in human cell lines.

What is the CAS number for Gemfibrozil?

The CAS number of Gemfibrozil is 25812-30-0.

What is Gemfibrozil (25812-30-0) used for?

Gemfibrozil is a peroxisome proliferator-activated receptor α (PPARα) and PPARγ agonist (EC50s = 193.3 and 147.8 μM, respectively, in transactivation assays). In vivo, gemfibrozil (50 mg/kg, p.o.) reduces serum total cholesterol, triglyceride, and LDL levels in a rat model of high-cholesterol diet-induced hyperlipidemia. Gemfibrozil (100 mg/kg per day) reduces atherosclerotic plaque area, superoxide production, and expression of the genes encoding the NF-κB subunit p65 and chemokine (C-C) motif ligand 2 (CCL2) in ApoE-/- mice. Formulations containing gemfibrozil have been used in the treatment of high cholesterol.InChI:InChI=1/C15H22O3/c1-11-6-7-12(2)13(10-11)18-9-5-8-15(3,4)14(16)17/h6-7,10H,5,8-9H2,1-4H3,(H,16,17)

What is the Gemfibrozil?

Gemfibrozil is White crystalline powder, while it's Molecular Formula is C15H22O3. White crystalline powder Gemfibrozil has been used to to study its effects on cell cycle progression in yeast. It has been used to study the effects of fibrates on cell proliferation and gene expression in human cell lines.

What is the CAS number for Gemfibrozil?

The CAS number of Gemfibrozil is 25812-30-0.

What is Gemfibrozil (25812-30-0) used for?

Gemfibrozil is a peroxisome proliferator-activated receptor α (PPARα) and PPARγ agonist (EC50s = 193.3 and 147.8 μM, respectively, in transactivation assays). In vivo, gemfibrozil (50 mg/kg, p.o.) reduces serum total cholesterol, triglyceride, and LDL levels in a rat model of high-cholesterol diet-induced hyperlipidemia. Gemfibrozil (100 mg/kg per day) reduces atherosclerotic plaque area, superoxide production, and expression of the genes encoding the NF-κB subunit p65 and chemokine (C-C) motif ligand 2 (CCL2) in ApoE-/- mice. Formulations containing gemfibrozil have been used in the treatment of high cholesterol.InChI:InChI=1/C15H22O3/c1-11-6-7-12(2)13(10-11)18-9-5-8-15(3,4)14(16)17/h6-7,10H,5,8-9H2,1-4H3,(H,16,17)

Product Class

25812-30-0

Product Name：Gemfibrozil
Molecular Formula：C₁₅H₂₂O₃
Purity：99%
Molecular Weight：250.338

Inquiry

Product Details:

CasNo： 25812-30-0

Molecular Formula： C₁₅H₂₂O₃

Appearance： White crystalline powder

Buy Best Quality Gemfibrozil 25812-30-0 In Bulk Supply

Molecular Formula:C15H22O3
Molecular Weight:250.338
Appearance/Colour:White crystalline powder
Vapor Pressure:6.13E-07mmHg at 25°C
Melting Point:61-63 °C
Refractive Index:1.511
Boiling Point:394.7 °C at 760 mmHg
PKA:4.75±0.45(Predicted)
Flash Point:141.6 °C
PSA：46.53000
Density:1.044 g/cm³
LogP:3.57320

Gemfibrozil(Cas 25812-30-0) Usage

Description	Gemfibrozil is a lipid-regulating agent used primarily to lower triglyceride levels in patients with hypertriglyceridemia and dyslipidemia. It is indicated for reducing the risk of developing coronary heart disease (CHD), particularly in patients with high lipid levels who are at risk for atherosclerosis but do not have existing CHD symptoms. Gemfibrozil works by activating peroxisome proliferator-activated receptors (PPARα and PPARγ), which play a key role in lipid metabolism.
Chemical properties	Physical Appearance: Crystallized from hexane, with a melting point of 61-63°C and a boiling point of 158-159°C at reduced pressure. Mechanism of Action: Gemfibrozil activates PPARα, increasing the oxidation of fatty acids and reducing the production of triglycerides. This action results in a decrease in very-low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) cholesterol levels while promoting an increase in high-density lipoprotein (HDL) cholesterol.
Uses	Gemfibrozil is effective in reducing very high serum triglyceride levels, making it useful in the management of hypertriglyceridemia and prevention of related complications such as pancreatitis. By lowering lipid levels, Gemfibrozil helps reduce the risk of atherosclerosis and coronary heart disease in high-risk patients, especially those without prior symptoms but with elevated lipid levels. Hangzhou Huarong Pharm Co., Ltd. established since 2009 , has been always focusing on supplying products and services to our clients in the field of small molecule drug. Huarong Pharm has successfully delivered innovative R&D products and services to more than 3,000 partners across the world. Our goal is to become a world-class leading company to support life science innovation and manufacturing.
Lipid Regulation	Gemfibrozil acts as an agonist of PPARα and PPARγ, which regulate the expression of genes involved in lipid metabolism. This results in enhanced clearance of triglyceride-rich particles from the blood and reduced synthesis of VLDL. It also promotes the synthesis of HDL, known as "good cholesterol."
Brand name	Lopid (Pfizer);Gevilon;Hipolixan;Ipolipid;Lipur;Tenorac.
Therapeutic Function	Antihyperlipidemic

InChI:InChI=1/C15H22O3/c1-11-6-7-12(2)13(10-11)18-9-5-8-15(3,4)14(16)17/h6-7,10H,5,8-9H2,1-4H3,(H,16,17)

25812-30-0 Relevant articles

A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis

Metin Basaranoglu1 basaranoglu@hotmail.com ∙ Ozer Acbay2 ∙ Abdullah Sonsuz1

, CorrespondenceVolume 31, Issue 2p384August 1999

We read with interest the review article by James & Day (1) about non-alcoholic steatohepatitis (NASH). We agree that, as mentioned in the article, NASH is a progressive necroinflammatory liver disease which is frequently seen in clinical practice (2–6). Although a few drugs have been tested in patients with NASH, there is currently no accepted form of medical therapy (7).

Mechanism of action of gemfibrozil on lipoprotein metabolism.

K Saku, P S Gartside, B A Hynd, and M L Kashyap

The Journal of Clinical Investigation, 1985

Each patient was admitted to the Clinical Research Center with metabolic kitchen facilities, for investigation of HDL and TG metabolism immediately before and after 8 wk of gemfibrozil treatment. Gemfibrozil significantly increased plasma HDL cholesterol, apolipoprotein (apo) AI, and apo AII by 36%, 29%, and 38% from base line, respectively. Plasma TG decreased by 54%.

Gemfibrozil greatly increases plasma concentrations of cerivastatin

Janne T. Backman MD, Carl Kyrklund MB, Mikko Neuvonen MSc, Pertti J. Neuvonen MD

Clinical Pharmacology & Therapeutics, Volume72, Issue6 December 2002 Pages 685-691

In a randomized, double-blind crossover study, 10 healthy volunteers took 600 mg gemfibrozil or placebo twice daily for 3 days. On day 3, each subject ingested a single 0.3-mg dose of cerivastatin. Plasma concentrations of cerivastatin, its metabolites, and gemfibrozil were measured up to 24 hours.

25812-30-0 Upstream products

169295-45-8
2,2-dimethyl-5-(2,5-dimethylphenoxy)-3-hydroxypentanoic acid β-lactone
201230-82-2
carbon monoxide
172533-96-9
2-methyl-5-(2,5-dimethylphenoxy)-2-pentene
95-87-4
2,5-Dimethylphenol